Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Feb;25(1):80-86.

Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients

Hongmei Zhang  1 , Chenchen Chen, Shuyuan Wang, Xiaoxia Li, Tingting Fan
Affiliations
  • PMID: 32277617

Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients

Hongmei Zhang et al. J BUON. 2020 Jan-Feb.

Abstract

Purpose: To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients.

Methods: A total of 100 ovarian cancer patients treated in our hospital from January 2015 to December 2018 were enrolled and divided into experimental group (n=50) and control group (n=50) using a random number table. Patients in the control group were treated with carboplatin alone, while those in the experimental group were treated with bevacizumab combined with nedaplatin, based on the treatment in the control group. The efficacy, adverse reactions and quality of life (QoL) score of patients were observed. Moreover, the levels of serum human epididymis protein 4 (HE4), alpha fetoprotein (AFP) and macrophage migration inhibitory factor (MIF), tumor markers carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and CA19.9, immunity indexes cluster of differentiation 3+ (CD3+), CD4+, CD8+ and natural killer (NK) cells, and serum inflammatory factors interleukin-8 (IL-8), IL-6 and IL-10 were detected before and after therapy.

Results: In the experimental group, the efficacy was superior to that in control group (p<0.05), and the adverse reactions were significantly reduced (p<0.05), while the QoL score was significantly increased (p<0.05). Before treatment, there were no significant differences in the levels of HE4, AFP and MIF, tumor markers CA125, CEA and CA19.9, immunity indexes CD3+, CD4+, CD8+ and NK cells, and inflammatory factors IL-8, IL-6 and IL-10 between the two groups (p>0.05). After treatment, the levels of HE4, AFP and MIF, CA125, CEA and CA19.9 and inflammatory factors IL-8, IL-6 and IL-10 obviously declined in the experimental group compared with the control group (p<0.05), while the levels of immunity indexes CD3+, CD4+, CD8+ and NK cells were clearly increased (p<0.05).

Conclusion: Bevacizumab combined with nedaplatin has good efficacy in the treatment of ovarian cancer, which can significantly improve the tumor markers, enhance the immunity and ameliorate the QoL of patients, with fewer adverse reactions, so it is worthy of popularization and application.

PubMed Disclaimer

MeSH terms